Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek
Rhea-AI Summary
Caris Life Sciences (NASDAQ: CAI) published a study in The Oncologist on the Caris Lookback Program, which continuously re-evaluates prior Caris MI Cancer Seek tests as new biomarker‑drug approvals emerge.
From >483,000 profiles, the program found 13,293 patients potentially eligible for newly approved targeted therapies across 10 tumor types, about 40% in non‑small cell lung cancer, using multi‑modal profiling such as WES, WTS and IHC. MI Cancer Seek is described as the first and only simultaneous WES+WTS‑based assay with FDA‑approved CDx indications for solid tumors, available for adults and children aged 1 and older.
AI-generated analysis. Not financial advice.
Positive
- Caris Lookback review of >483,000 molecular profiles since 2014
- Identification of 13,293 patients potentially eligible for new targeted therapies
- Analysis of 87 biomarker‑directed FDA approvals from 2018–2025
- Approximately one‑third of evaluated approvals integrated into Lookback framework
- Around 40% of identified opportunities in non‑small cell lung cancer
- MI Cancer Seek WES+WTS assay with FDA‑approved CDx indications for solid tumors
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
CAI is up 3.81% while key biotech peers show mixed moves: MDGL +3.36%, MRNA +1.07%, ROIV +0.89%, VRNA +0.06%, and HALO -1.17%. With no peers in the momentum scanner and no same-day peer news, today’s move appears more company-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 11 | Clinical study data | Positive | -1.3% | Study showed WES-based TMB better predicts pembrolizumab benefit than gene panels. |
| May 08 | Regulatory submission | Positive | -1.3% | Submitted Caris Assure blood-based profiling application to NY State health authorities. |
| May 07 | Earnings results | Positive | -18.6% | Reported strong Q1 2026 revenue growth, high gross margin, and positive cash generation. |
| May 05 | AI product launch | Positive | +1.4% | Launched Caris MI Clarity, an AI test for early and late recurrence risk in breast cancer. |
| May 04 | Reimbursement milestone | Positive | +1.2% | Caris ChromoSeq received MolDX approval, supporting broader access and reimbursement. |
Recent history shows largely positive operational and scientific news, yet price reactions have been mixed, with strong fundamental updates (including earnings) sometimes followed by notable sell-offs.
Over the last two weeks, CAI has released multiple positive updates, including MolDX approval for Caris ChromoSeq on May 4, launch of AI-powered Caris MI Clarity on May 5, and strong Q1 2026 financial results on May 7 with rapid revenue growth and positive cash flow. Subsequent scientific publications and regulatory submissions on biomarker-driven profiling further highlighted the platform. Today’s Lookback Program study reinforces this theme of leveraging large-scale multimodal profiling for ongoing clinical value.
Market Pulse Summary
This announcement highlights the Caris Lookback Program’s ability to translate historical profiling into ongoing clinical value, identifying 13,293 potentially eligible patients across 10 tumor types from more than 483,000 molecular profiles. It reinforces MI Cancer Seek as a simultaneous WES/WTS assay with FDA-approved CDx indications and underscores the importance of multi-modal testing. Investors may track how such real-world utility, alongside recent earnings strength and product launches, affects long-term adoption and case volumes.
Key Terms
whole exome sequencing (wes) medical
whole transcriptome sequencing (wts) medical
immunohistochemistry (ihc) medical
molecular profiling medical
fda-approved cdx regulatory
biomarker‑linked therapies medical
AI-generated analysis. Not financial advice.
The Caris Lookback Program identified 13,293 patients potentially eligible for newly approved targeted therapies across 10 tumor types
Molecular profiling reports from most labs are static, reflecting clinical knowledge only at the time of testing. As new biomarker–drug associations and therapeutic indications emerge, patients with previously identified biomarkers may miss newly approved treatment opportunities, while clinicians face increasing challenges staying current with evolving evidence.
Since 2014, Caris patients have benefited from the dynamic Caris Lookback Program, which addresses limitations of static molecular profiling reports. Through this program, Caris continuously monitors new FDA approvals and guideline updates regarding biomarker‑linked therapies. When new clinical actionability is identified, Caris retrospectively reviews prior patient test results to identify those patients whose molecular profiles align with the new or updated recommendations, all without the need for additional testing. Treating oncologists are then proactively notified through coordinated Medical Affairs and Molecular Science Liaison (MSL) outreach. Caris patients can therefore benefit long after testing has occurred and oncologists can benefit from updated therapeutic insights.
"As the number of biomarker‑driven therapies continues to accelerate, a static analysis limited to a single moment‑in‑time is no longer sufficient in many cases," said James Hamrick, MD, MPH, Chairman, Caris Precision Oncology Alliance. "The Caris Lookback Program was designed to extend the clinical value of comprehensive molecular profiling over time by continuously reviewing prior results through the lens of newly emerging therapeutic evidence, helping ensure that patients and their physicians can benefit from ongoing advances in precision oncology."
In this large real‑world analysis, Caris evaluated 87 biomarker‑directed FDA approvals between 2018 and 2025 using a structured clinical impact framework. Approximately one-third of these approvals met criteria for inclusion in the Caris Lookback Program based on their potential clinical value and actionability. From a database of more than 483,000 molecular profiles, the program identified 13,293 patients potentially eligible for newly approved targeted therapies across 10 tumor types and multiple tumor‑agnostic indications.
The program's impact spanned a broad range of solid tumors, including non‑small cell lung, breast, colorectal and pancreatic cancers, with non‑small cell lung cancer accounting for approximately
Beyond molecular identification, the study also demonstrated the effectiveness of proactive clinical engagement. By integrating comprehensive molecular profiling with continuous evidence surveillance and targeted physician engagement, the Caris Lookback Program demonstrates how a single comprehensive test can deliver dynamic, longitudinal clinical utility, helping identify patients who may benefit from newly approved therapies without repeat biopsies or additional testing.
MI Cancer Seek® is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved CDx indications for molecular profiling of solid tumors. MI Cancer Seek is available for adult and pediatric patients (ages 1+).
About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.
Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606
View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-publishes-study-on-the-caris-lookback-program-demonstrating-the-ongoing-clinical-value-of-comprehensive-testing-with-caris-mi-cancer-seek-302773279.html
SOURCE Caris Life Sciences